Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

Infection

Volumn 45, Issue 1, 2017, Pages 115-117

  Hernández Tejedor, Alberto ^a   Merino Vega, Carmen Débora ^a   Martín Vivas, Alfredo ^a   Ruiz de Luna González, Rafael ^a   Delgado Iribarren, Alberto ^a   Gabán Díez, Ángeles ^a   Temprano Gómez, Ignacio ^a   de la Calle Pedrosa, Natalia ^a   González Jiménez, Ana Isabel ^a   Algora Weber, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Bacteremia; Ceftolozane tazobactam; Multidrug resistant Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; METHYLPREDNISOLONE; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIUM CULTURE; BLOOD CULTURE; BRONCHIAL ASPIRATION PROCEDURE; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; DECUBITUS; FEVER; HOSPITAL ADMISSION; HUMAN; INFLUENZA A VIRUS; INTENSIVE CARE UNIT; LEUKOCYTOSIS; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; OFF LABEL DRUG USE; PRONE POSITION; PSEUDOMONAS INFECTION; RESPIRATORY DISTRESS SYNDROME; TRACHEOBRONCHITIS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFF-LABEL USE; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84991338328     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0944-5     Document Type: Article

References (5)

1. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (MK-7625A-008) (ASPECT-NP). https://clinicaltrials.gov/ct2/show/NCT02070757. Accessed 30 May 2016.
2. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–5.
3. Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
4. Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy. 2016;36:e30–3.
5. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane–tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218–23.